She related the onset to significant stress at her job. Unknown. Biopsy showed lichen simplex chronicus. There are no clinical manifestations. Some areas of the skin may be predisposed to pruritus ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

Biopsy specimens from the labia majora and the vulva showed chronic dermatitis and lichen simplex chronicus. The patient denied having used tampons, pads, douches, condoms, or other genital ...

It’s also important to avoid scratching, as this may contribute to a condition called lichen simplex chronicus which can further exacerbate the itching sensation There’s no single timeline for ...

Lichen simplex chronicus is a chronic, inflammatory skin condition characterized by scaly, thickened skin of the vulva (a term that refers to all the structures of the female external genitalia). It ...

Ahead, 10 itches you should never scratch. Get The Healthy by Reader's Digest newsletter  Itches you shouldn't scratch 1.